Last reviewed · How we verify
NCT06210243
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Phase 1 trial testing C752 in Lymphoma, B-Cell in 2 participants. Terminated before completion.
24 December 2024
Quick facts
| Lead sponsor | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2 |
| Start date | 24 December 2023 |
| Primary completion | 24 December 2024 |
| Estimated completion | 24 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- C752 — full drug profile →
Conditions studied
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
- CAR-T — all drugs for CAR-T →
Sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Who can join
18 and older, any sex, with Lymphoma, B-Cell or CAR-T. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06210243
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphoma, B-Cell
Currently open trials in the same condition.
- NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
- NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
- NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
- NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
Other 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China trials
Trials by the same sponsor.
- NCT06675422 — JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) · Phase 1, PHASE2 · recruiting
- NCT06514768 — JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL) · EARLY_PHASE1 · recruiting
- NCT06352281 — Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) · Phase 1, PHASE2 · recruiting
- NCT06110208 — Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML · EARLY_PHASE1 · terminated
- NCT05932173 — A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06210243 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Last refreshed: 18 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06210243.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing